Cytokine-secreting tumor cell vaccines

Current Opinion in Immunology

Volumn 12, Issue 5, 2000, Pages 571-575

  Mach, Nicolas ^a   Dranoff, Glenn ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CARCINOGEN; CD40 ANTIGEN; CYTOKINE; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; TOXIN; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; CELLULAR IMMUNITY; CLINICAL TRIAL; GENE; GENE TRANSFER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LEUKOCYTE; NONHUMAN; REVIEW; TUMOR; TUMOR VASCULARIZATION; VACCINATION;

EID: 0033821972     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00144-8     Document Type: Review

References (56)

1. Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy
2. Gene transfer as cancer therapy
3. Differential tumor surveillance by natural killer (NK) and NKT cells
4. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene
5. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinoma in two lines of her-2/neu transgenic mice
6. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12
7. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity
8. Requirement for V(α)14 NKT cells in IL-12-mediated rejection of tumors
9. In vivo natural killer cell activities revealed by natural killer cell-deficient mice
10. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect
11. Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine
12. Interferon γ-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony-stimulating factor
13. IgG2a induced by interleukin (IL) 12-produced tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases
14. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA
15. In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: Comparison with purified native GM-CSF
16. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
17. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
18. Dendritic cells and the control of immunity
19. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand
20. Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1α and accumulation of dendritic cells at vaccination sites in vivo
21. Induction of chemokine secretion and enhancement of contact-dependent macrophage cytotoxicity by engineered expression of granulocyte-macrophage colony-stimulating factor in human colon cancer cells
22. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
23. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
24. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154
25. Conversion of tumor-specific CD4(+) T-cell tolerance to T-cell priming through in vivo ligation of CD40
26. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
27. Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma
28. + T cells in the antitumor immune response
29. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
30. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer
31. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor
32. A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy
33. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy
34. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors
35. New paths in human cancer serology
36. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
37. Search for common antigenicity among twenty-five sarcomas induced by methylcholanthrene
38. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma
39. Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma
40. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells
41. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma
42. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
43. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study
44. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
45. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer
46. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts
47. Gene therapy of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors
48. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells
49. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability
50. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
51. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma
52. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant
53. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine
54. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
55. Model predicting survival in stage I melanoma based on tumor progression
56. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer